Deciphex Raises €31M in Series C Funding to Expand AI-Powered Digital Pathology Solutions
Deciphex is at the forefront of digital pathology, driving efficiency and innovation in both clinical diagnostics and drug development.
Company Name: Deciphex
Location: Dublin, Ireland
Industry: AI-Powered Digital Pathology
Funding Details:
Amount: €31M (Series C)
Investors: Molten Ventures (Lead), ACT Venture Capital, Seroba, Charles River Laboratories (NYSE: CRL), IRRUS Investments, HBAN Medtech Syndicate, Nextsteps Capital
Purpose of Investment:
The funds will be used to:
- Scale global service reach
- Enhance platform utility
- Accelerate pathology AI foundational model development
- Strengthen partnerships with industry leaders
- Expand services to Pharma/Biotech and CRO clients
Leadership:
CEO and Founder: Donal O’Shea
Product:
Deciphex leverages AI to transform diagnostic workflows and improve patient outcomes. Its two flagship platforms include:
- Diagnexia: Connecting global subspecialty pathologists for rapid diagnostics and backlog reduction.
- Patholytix: Accelerating drug development by optimizing preclinical safety assessments for Pharma/Biotech and CRO clients.
Impact:
By automating routine pathology tasks, Deciphex enables pathologists to concentrate on complex cases, delivering faster, more accurate diagnoses. Its platforms merge AI innovation with clinical expertise to advance healthcare delivery and therapeutic development.
About the Company:
Deciphex is at the forefront of digital pathology, driving efficiency and innovation in both clinical diagnostics and drug development. With its Series C funding, the company is set to expand its global impact and lead advancements in AI-powered pathology solutions.
